E Fund Management Co., Ltd. Cel Sci Corp Transaction History

E Fund Management Co., Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$7.1 - $12.82 $83,652 - $151,045	-11,782 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$7.64 - $12.49 $43,968 - $71,879	5,755 Added 95.49%	11,782 $129,000
Q1 2021 May 12, 2021	BUY	$12.0 - $27.64 $72,324 - $166,586	6,027 New	6,027 $91,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.